PTC Therapeutics, Inc. (PTCT) News
Filter PTCT News Items
PTCT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
PTCT News Highlights
- For PTCT, its 30 day story count is now at 6.
- Over the past 13 days, the trend for PTCT's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about PTCT are PTC, BIIB and DEC.
Latest PTCT News From Around the Web
Below are the latest news stories about PTC THERAPEUTICS INC that investors may wish to consider to help them evaluate PTCT as an investment opportunity.
Biogen's (BIIB) Rare Disease Drug Skyclarys Gets CHMP Nod in EUBiogen (BIIB) gets positive CHMP opinion recommending marketing authorization to Skyclarys in the EU for the treatment of Friedreich's ataxia in patients aged 16 years and older. |
Insider Buying: CFO Pierre Gravier Acquires 7,700 Shares of PTC Therapeutics Inc (PTCT)In the realm of stock market movements, insider trading activity is often a significant indicator that can provide insights into a company's potential future performance. |
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 10, 2023, the company approved non-statutory stock options to purchase an aggregate of 3,575 shares of its common stock and 3,035 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to two new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation. |
Solid Biosciences' (SLDB) DMD Drug Gets Fast Track Tag, Stock UpSolid Biosciences (SLDB) gains 68% as the FDA grants Fast Track designation to the company's gene therapy candidate, SGT-003, for the treatment of Duchenne muscular dystrophy. |
PTC Therapeutics Provides Updates on Translarna™ Regulatory ActivitiesPTC Therapeutics, Inc. (NASDAQ: PTCT) announced today an update on Translarna™ (ataluren) regulatory activities in Europe and the United States. |
PTC Therapeutics (NASDAQ:PTCT) shareholders are up 17% this past week, but still in the red over the last three yearsPTC Therapeutics, Inc. ( NASDAQ:PTCT ) shareholders should be happy to see the share price up 28% in the last month... |
PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call TranscriptPTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call Transcript October 29, 2023 Operator: Thank you for standing by and welcome to the PTC Therapeutics Third Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] Please be […] |
Why Is PTC Therapeutics (PTCT) Stock Down 23% Today?PTC Therapeutics stock is falling on Friday as PTCT investors react to the company's lackluster earnings report for Q3 2023. |
ALGN Stock Alert: Align Technology Announces $250M Stock Buyback ProgramAlign Technology stock is rising on Friday after the company announced plans to repurchase $250 million worth of ALGN shares. |
RBLX Stock Alert: Analysts Are Pounding the Table on RobloxRoblox stock is rising higher on Friday after analysts upgraded shares of RBLX and increased price targets for the gaming company. |